BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a
biotechnology company focusing its efforts on immuno-oncology through the
development of targeted, safe treatment options for cancer, has been working
diligently to advance its clinical program. A recent article discussing the
company reads, “The company attained crucial safety and efficacy data via its
clinical trials, and it also achieved proof of concept. The phase I/IIa study
of its proof of concept clinical trial in advanced breast cancer achieved
sustained tumor shrinkage at various sites in several patients. These results
confirm the data collected through two previous trials, demonstrating the
promising effect of the company’s Bria-IMT therapy in the treatment of
advanced, metastatic breast cancer.”
To view the full article, visit http://ibn.fm/H8eCa
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company
developing targeted and safe approaches for the management of cancer. BriaCell
is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead
candidate, in a combination study with pembrolizumab [Keytruda; manufactured by
Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers
Squibb Company]. The combination study is listed in ClinicalTrials.gov as
NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized
immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments
are personalized to match the patient without the need for personalized
manufacturing. Bria-OTS, which is expected to cover over 90 percent of the
patient population, is designed to produce a potent and selective immune
response against the cancer of each patient while eliminating the time,
expense, and complex manufacturing logistics associated with other personalized
immunotherapies. For more information, visit the company’s website at www.BriaCell.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.p
No comments:
Post a Comment